Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by RPINVESTOR1on Aug 17, 2019 10:05am
65 Views
Post# 30039361

RE:RE:RE:RE:RE:RE:RE:Painful Wait

RE:RE:RE:RE:RE:RE:RE:Painful WaitTo me, the fact that there has not been an update is a positive. My reading on this is that Replicel and Shiseido are in talks. Assuming that Shiseido has good results, they are going to get hundreds of millions of dollars of free publicity from the media. There is no point in releasing the results of the trial, getting the free publicity and then having a long fight with the patent holder before finally bringing (after lawsuits, etc.) the technology to the market place. 

Shiseido should get their 'ducks in line' before making any announcement. This includes a deal of some type with Replicel. They can then present their findings at a scientific conference, receive the free publicity and then quickly move on to offering the treatment to the public. 
Bullboard Posts